Imprint  |  Sitemap  |  Search


Welcome to AiCuris

Clear Focus on Anti-Infective Cures

AiCuris (name derived from 'anti-infective cures') is a pharmaceutical company focused exclusively on the discovery, research and development of novel antiviral and antibacterial agents for the treatment of severe and potentially life-threatening infectious diseases. AiCuris has its roots in Bayer's long history of successful anti-infective drugs. It is built around Bayer's portfolio of antiviral and antibacterial R&D programs, compounds and intellectual property and it is run by experts from Bayer's virology and bacteriology research. CEO of AiCuris is Prof. Dr. Helga Rübsamen-Schaeff, the former Senior Vice President and Head of Anti-Infective Research at Bayer. Majority investors are Drs. Strüngmann, the founders and previous owners of Hexal.

With its

  • broad and 100 % innovative pipeline from one of the leading pharmaceutical companies in the field of anti-infectives
  • concentration on specialist markets with high medical need
  • team of internationally highly recognized scientists with the knowhow of major pharmaceutical companies
  • and the support by its majority investors, the Drs. Strüngmann,

AiCuris is primed to prosper and to bring innovative drugs to the market for patients with severe, life-threatening infections.

AiCuris is a member of BioDeutschland

AiCuris was one of the participating companies at the first Innovation Prize of the german economy in 2011



The substantial number of antibacterial agents identified and developed during the second half of the last century has seemingly fulfilled the requirements to combat the vast majority of common infections ...

learn more


In recent years, the threat of a viral epidemic or even a pandemic has become more of a reality than ever before. The appearance and spreading of HIV has alerted the general public to the evils of pathogenic viruses ...

learn more